Related scientific articles (all)

PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors.

Authors : Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J
Year : 2017
Journal : Cancer Res
Volume : 77(2)
Pages : 312-9

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Authors : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, DHondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Year : 2017
Journal : Clin Genitourin Cancer
Volume : 15(4)
Pages : 502-508

Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma.

Authors : Vouche M, Degrez T, Bouazza F, Delatte P, Gomez Galdon M, Hendlisz A, Flamen P, Donckier V
Year : 2017
Journal : World J Hepatol
Volume : 9
Pages : 1372-1377

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors : Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M
Year : 2017
Journal : Lancet Oncol
Volume : 18(7)
Pages : 904-916

Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Authors : Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, Van Velthoven R
Year : 2017
Journal : BJU Int
Volume : 120(2)
Pages : 197-203

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Authors : Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart-Gebhart M, de Vries EGE, Latino NJ, Douillard JY, Cherny NI
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000216

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Year : 2017
Journal : N Engl J Med
Volume : 377(2)
Pages : 122-131

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Authors : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Year : 2017
Journal : Ann Oncol
Volume : 28(1)
Pages : 16-33

Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.

Authors : Awada G, de Azambuja E, Awada A
Year : 2017
Journal : Expert Opin Drug Metab Toxicol
Volume : 13(12)
Pages : 1205-1215

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.

Authors : Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K
Year : 2017
Journal : JCI Insight
Volume : 2

Recurrence dynamics of breast cancer according to baseline body mass index.

Authors : Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, Closon-Dejardin MT, Kerger J, Focan C, Di Leo A, Nogaret JM, Sotiriou C, Piccart-Gebhart M, Demicheli R
Year : 2017
Journal : Eur J Cancer
Volume : 87
Pages : 10-20

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Authors : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Year : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pages : 6411-6420

Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.

Authors : Kourie HR, Ameye L, Paesmans M, Bron D
Year : 2017
Journal : Br J Haematol
Volume : 179 (5)
Pages : 846-848

PRIMA-1 and PRIMA-1 Met(APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Authors : Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M
Year : 2017
Journal : Cancers (Basel)
Volume : 9

The meaningness of colon cancer sidedness.

Authors : Hendlisz A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29
Pages : 286-287

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Authors : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Year : 2017
Journal : Breast
Volume : 31
Pages : 244-259

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Authors : Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart-Gebhart M, Von Minckwitz G, Baselga J, Loi S
Year : 2017
Journal : Eur J Cancer
Volume : 85
Pages : 133-145

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Authors : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Year : 2017
Journal : Nat Commun
Volume : 8
Pages : 15759

Concurrent driver mutations/rearrangements in non-small-cell lung cancer.

Authors : Tabchi S, Kourie HR, Klastersky J
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(2)
Pages : 118-22

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Authors : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Year : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15